Cite
Silencing of STE20‐type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet‐induced nonalcoholic fatty liver disease.
MLA
Caputo, Mara, et al. “Silencing of STE20‐type Kinase MST3 in Mice with Antisense Oligonucleotide Treatment Ameliorates Diet‐induced Nonalcoholic Fatty Liver Disease.” FASEB Journal, vol. 35, no. 5, May 2021, pp. 1–17. EBSCOhost, https://doi.org/10.1096/fj.202002671RR.
APA
Caputo, M., Kurhe, Y., Kumari, S., Cansby, E., Amrutkar, M., Scandalis, E., Booten, S. L., Ståhlman, M., Borén, J., Marschall, H., Aghajan, M., & Mahlapuu, M. (2021). Silencing of STE20‐type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet‐induced nonalcoholic fatty liver disease. FASEB Journal, 35(5), 1–17. https://doi.org/10.1096/fj.202002671RR
Chicago
Caputo, Mara, Yeshwant Kurhe, Sima Kumari, Emmelie Cansby, Manoj Amrutkar, Eli Scandalis, Sheri L. Booten, et al. 2021. “Silencing of STE20‐type Kinase MST3 in Mice with Antisense Oligonucleotide Treatment Ameliorates Diet‐induced Nonalcoholic Fatty Liver Disease.” FASEB Journal 35 (5): 1–17. doi:10.1096/fj.202002671RR.